;PMID: 6436502
;source_file_883.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..166] = [t:52..166]
;2)section:[e:170..219] = [t:170..219]
;3)sentence:[e:223..473] = [t:223..473]
;4)sentence:[e:474..543] = [t:474..543]
;5)sentence:[e:544..611] = [t:544..611]
;6)sentence:[e:613..752] = [t:613..752]
;7)sentence:[e:753..840] = [t:753..840]
;8)sentence:[e:841..957] = [t:841..957]
;9)sentence:[e:958..1066] = [t:958..1066]
;10)sentence:[e:1067..1173] = [t:1067..1173]
;11)sentence:[e:1174..1282] = [t:1174..1282]
;12)sentence:[e:1283..1379] = [t:1283..1379]
;13)sentence:[e:1380..1504] = [t:1380..1504]
;14)sentence:[e:1505..1612] = [t:1505..1612]
;15)sentence:[e:1613..1863] = [t:1613..1863]
;16)section:[e:1867..1911] = [t:1867..1911]

;section 0 Span:0..46
;J Toxicol Environ Health. 1984;13(4-6):649-57.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Toxicol) (NNP:[10..17] Environ)
        (NNP:[18..24] Health) (.:[24..25] .) (CD:[26..30] 1984)
        (CD:[30..35] ;13-LRB-4) (::[35..36] -) (CD:[36..38] 6-RRB-)
        (CD:[38..42] :649) (::[42..43] -) (CD:[43..45] 57) (.:[45..46] .)))

;sentence 1 Span:52..166
;Effect of dose on the inhibition of carcinogenesis/mutagenesis by Aroclor
;1254  in rainbow trout fed aflatoxin B1.
;[118..130]:substance:"Aroclor 1254"
;[153..165]:substance:"aflatoxin B1"
(SENT
  (NP-HLN
    (NP (NN:[52..58] Effect))
    (PP (IN:[59..61] of)
      (NP (NN:[62..66] dose)))
    (PP (IN:[67..69] on)
      (NP
        (NP (DT:[70..73] the) (NN:[74..84] inhibition))
        (PP (IN:[85..87] of)
          (NP (NN:[88..102] carcinogenesis) (SYM:[102..103] /)
              (NN:[103..114] mutagenesis)))
        (PP (IN:[115..117] by)
          (NP (NN:[118..125] Aroclor) (CD:[126..130] 1254)))))
    (PP (IN:[132..134] in)
      (NP
        (NP (NN:[135..142] rainbow) (NNS:[143..148] trout))
        (VP (VBN:[149..152] fed)
          (NP (-NONE-:[152..152] *))
          (NP (NN:[153..162] aflatoxin) (NN:[163..165] B1)))))
    (.:[165..166] .)))

;section 2 Span:170..219
;Shelton DW, Hendricks JD, Coulombe RA, Bailey GS.
(SEC
  (FRAG (NNP:[170..177] Shelton) (NNP:[178..180] DW) (,:[180..181] ,)
        (NNP:[182..191] Hendricks) (NNP:[192..194] JD) (,:[194..195] ,)
        (NNP:[196..204] Coulombe) (NNP:[205..207] RA) (,:[207..208] ,)
        (NNP:[209..215] Bailey) (NNP:[216..218] GS) (.:[218..219] .)))

;sentence 3 Span:223..473
;Prior studies have shown that Aroclor 1254 (PCB) differentially alters the 
;incidence of aflatoxin B1 (AFB1) induced hepatocellular carcinomas in trout, 
;depending upon the time of PCB administration relative to AFB1 exposure
;(Shelton  et al., 1983).
;[253..265]:substance:"Aroclor 1254"
;[267..270]:substance:"PCB"
;[312..324]:substance:"aflatoxin B1"
;[326..330]:substance:"AFB1"
;[404..407]:substance:"PCB"
;[435..439]:substance:"AFB1"
(SENT
  (S
    (NP-SBJ-1 (JJ:[223..228] Prior) (NNS:[229..236] studies))
    (VP (VBP:[237..241] have)
      (VP (VBN:[242..247] shown)
        (SBAR (IN:[248..252] that)
          (S
            (NP-SBJ
              (NP (NN:[253..260] Aroclor) (CD:[261..265] 1254))
              (NP (-LRB-:[266..267] -LRB-) (NN:[267..270] PCB)
                  (-RRB-:[270..271] -RRB-)))
            (ADVP (RB:[272..286] differentially))
            (VP (VBZ:[287..293] alters)
              (NP
                (NP (DT:[294..297] the) (NN:[299..308] incidence))
                (PP (IN:[309..311] of)
                  (NP
                    (ADJP
                      (NML
                        (NML (NN:[312..321] aflatoxin) (NN:[322..324] B1))
                        (NML (-LRB-:[325..326] -LRB-) (NN:[326..330] AFB1)
                             (-RRB-:[330..331] -RRB-)))
                      (VBN:[332..339] induced))
                    (JJ:[340..354] hepatocellular) (NNS:[355..365] carcinomas))))
              (PP-LOC (IN:[366..368] in)
                (NP (NN:[369..374] trout)))
              (,:[374..375] ,)
              (S-ADV
                (NP-SBJ (-NONE-:[375..375] *))
                (VP (VBG:[377..386] depending)
                  (PP-CLR (IN:[387..391] upon)
                    (NP
                      (NP
                        (NP (DT:[392..395] the) (NN:[396..400] time))
                        (PP (IN:[401..403] of)
                          (NP (NN:[404..407] PCB) (NN:[408..422] administration))))
                      (ADJP (JJ:[423..431] relative)
                        (PP (TO:[432..434] to)
                          (NP (NN:[435..439] AFB1) (NN:[440..448] exposure))))))
                  (PRN (-LRB-:[449..450] -LRB-)
                    (FRAG (NNP:[450..457] Shelton) (FW:[459..461] et)
                          (FW:[462..465] al.) (,:[465..466] ,)
                          (CD:[467..471] 1983))
                    (-RRB-:[471..472] -RRB-)))))))))
    (.:[472..473] .)))

;sentence 4 Span:474..543
;When fed simultaneously with AFB1, PCB inhibits carcinoma  incidence.
;[503..507]:substance:"AFB1"
;[509..512]:substance:"PCB"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[474..478] When))
      (S
        (NP-SBJ-1 (-NONE-:[478..478] *))
        (VP (VBN:[479..482] fed)
          (NP-1 (-NONE-:[482..482] *))
          (ADVP (RB:[483..497] simultaneously))
          (PP (IN:[498..502] with)
            (NP (NN:[503..507] AFB1)))
          (ADVP-2 (-NONE-:[507..507] *T*)))))
    (,:[507..508] ,)
    (NP-SBJ (NN:[509..512] PCB))
    (VP (VBZ:[513..521] inhibits)
      (NP (NN:[522..531] carcinoma) (NN:[533..542] incidence)))
    (.:[542..543] .)))

;sentence 5 Span:544..611
;We investigated the effect of AFB1 and PCB dose on this inhibition.
;[574..578]:substance:"AFB1"
;[583..586]:substance:"PCB"
(SENT
  (S
    (NP-SBJ (PRP:[544..546] We))
    (VP (VBD:[547..559] investigated)
      (NP
        (NP (DT:[560..563] the) (NN:[564..570] effect))
        (PP (IN:[571..573] of)
          (NP
            (NP (NN:[574..578] AFB1)
              (NML-1 (-NONE-:[578..578] *P*)))
            (CC:[579..582] and)
            (NP (NN:[583..586] PCB)
              (NML-1 (NN:[587..591] dose)))))
        (PP (IN:[592..594] on)
          (NP (DT:[595..599] this) (NN:[600..610] inhibition)))))
    (.:[610..611] .)))

;sentence 6 Span:613..752
;Duplicate tanks of 100 rainbow trout were fed AFB1 at concentrations of 1, 4,
;or  8 ppb, either with or without the addition of 50 ppm PCB.
;[659..663]:substance:"AFB1"
;[685..686]:quantitative-value:"1"
;[688..689]:quantitative-value:"4"
;[695..696]:quantitative-value:"8"
;[697..700]:quantitative-units:"ppb"
;[741..743]:quantitative-value:"50"
;[744..747]:quantitative-units:"ppm"
;[748..751]:substance:"PCB"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[613..622] Duplicate) (NNS:[623..628] tanks))
      (PP (IN:[629..631] of)
        (NP (CD:[632..635] 100) (NN:[636..643] rainbow) (NNS:[644..649] trout))))
    (VP (VBD:[650..654] were)
      (VP (VBN:[655..658] fed)
        (NP-1 (-NONE-:[658..658] *))
        (NP
          (NP (NN:[659..663] AFB1))
          (PP (IN:[664..666] at)
            (NP
              (NP (NNS:[667..681] concentrations))
              (PP (IN:[682..684] of)
                (NP
                  (NP (CD:[685..686] 1)
                    (NML-2 (-NONE-:[686..686] *P*)))
                  (,:[686..687] ,)
                  (NP (CD:[688..689] 4)
                    (NML-2 (-NONE-:[689..689] *P*)))
                  (,:[689..690] ,) (CC:[691..693] or)
                  (NP (CD:[695..696] 8)
                    (NML-2 (NN:[697..700] ppb)))))))
          (,:[700..701] ,)
          (PP (CC:[702..708] either)
            (PP (IN:[709..713] with)
              (NP-3 (-NONE-:[713..713] *P*)))
            (CC:[714..716] or)
            (PP (IN:[717..724] without)
              (NP-3
                (NP (DT:[725..728] the) (NN:[729..737] addition))
                (PP (IN:[738..740] of)
                  (NP
                    (NML (CD:[741..743] 50) (NN:[744..747] ppm))
                    (NN:[748..751] PCB)))))))))
    (.:[751..752] .)))

;sentence 7 Span:753..840
;Other groups were fed  4 ppb AFB1 + 5 ppm PCB, 50 ppm PCB alone, or control
;diet alone.
;[776..777]:quantitative-value:"4"
;[778..781]:quantitative-units:"ppb"
;[782..786]:substance:"AFB1"
;[789..790]:quantitative-value:"5"
;[791..794]:quantitative-units:"ppm"
;[795..798]:substance:"PCB"
;[800..802]:quantitative-value:"50"
;[803..806]:quantitative-units:"ppm"
;[807..810]:substance:"PCB"
(SENT
  (S
    (NP-SBJ-1 (JJ:[753..758] Other) (NNS:[759..765] groups))
    (VP (VBD:[766..770] were)
      (VP (VBN:[771..774] fed)
        (NP-1 (-NONE-:[774..774] *))
        (NP
          (NP
            (NP
              (NML (CD:[776..777] 4) (NN:[778..781] ppb))
              (NN:[782..786] AFB1))
            (SYM:[787..788] +)
            (NP
              (NML (CD:[789..790] 5) (NN:[791..794] ppm))
              (NN:[795..798] PCB)))
          (,:[798..799] ,)
          (NP
            (NP
              (NML (CD:[800..802] 50) (NN:[803..806] ppm))
              (NN:[807..810] PCB))
            (ADVP (RB:[811..816] alone)))
          (,:[816..817] ,) (CC:[818..820] or)
          (NP
            (NP (NN:[821..828] control) (NN:[829..833] diet))
            (ADVP (RB:[834..839] alone))))))
    (.:[839..840] .)))

;sentence 8 Span:841..957
;After 9 and 12  mo, 40 and 60 fish per tank, respectively, were sampled to
;determine the  incidence of liver tumors.
;[847..848]:quantitative-value:"9"
;[853..855]:quantitative-value:"12"
;[857..859]:quantitative-units:"mo"
(SENT
  (S
    (PP-TMP (IN:[841..846] After)
      (NP
        (NP (CD:[847..848] 9)
          (NML-1 (-NONE-:[848..848] *P*)))
        (CC:[849..852] and)
        (NP (CD:[853..855] 12)
          (NML-1 (NN:[857..859] mo)))))
    (,:[859..860] ,)
    (NP-SBJ-3
      (NP
        (NP (CD:[861..863] 40)
          (NML-2 (-NONE-:[863..863] *P*)))
        (CC:[864..867] and)
        (NP (CD:[868..870] 60)
          (NML-2 (NNS:[871..875] fish))))
      (PP (IN:[876..879] per)
        (NP (NN:[880..884] tank))))
    (,:[884..885] ,)
    (ADVP (RB:[886..898] respectively))
    (,:[898..899] ,)
    (VP (VBD:[900..904] were)
      (VP (VBN:[905..912] sampled)
        (NP-3 (-NONE-:[912..912] *))
        (S-PRP
          (NP-SBJ (-NONE-:[912..912] *))
          (VP (TO:[913..915] to)
            (VP (VB:[916..925] determine)
              (NP
                (NP (DT:[926..929] the) (NN:[931..940] incidence))
                (PP (IN:[941..943] of)
                  (NP (NN:[944..949] liver) (NNS:[950..956] tumors)))))))))
    (.:[956..957] .)))

;sentence 9 Span:958..1066
;The results show a parallel inhibition of the  AFB1-tumor dose-response curve
;by the presence of 50 ppm PCB.
;[1005..1009]:substance:"AFB1"
;[1055..1057]:quantitative-value:"50"
;[1058..1061]:quantitative-units:"ppm"
;[1062..1065]:substance:"PCB"
(SENT
  (S
    (NP-SBJ (DT:[958..961] The) (NNS:[962..969] results))
    (VP (VBP:[970..974] show)
      (NP
        (NP (DT:[975..976] a) (JJ:[977..985] parallel)
            (NN:[986..996] inhibition))
        (PP (IN:[997..999] of)
          (NP (DT:[1000..1003] the)
            (NML (NN:[1005..1009] AFB1) (HYPH:[1009..1010] -)
                 (NN:[1010..1015] tumor))
            (NML
              (NML (NN:[1016..1020] dose))
              (PP (HYPH:[1020..1021] -)
                (NP (NN:[1021..1029] response))))
            (NN:[1030..1035] curve)))
        (PP (IN:[1036..1038] by)
          (NP
            (NP (DT:[1039..1042] the) (NN:[1043..1051] presence))
            (PP (IN:[1052..1054] of)
              (NP
                (NML (CD:[1055..1057] 50) (NN:[1058..1061] ppm))
                (NN:[1062..1065] PCB)))))))
    (.:[1065..1066] .)))

;sentence 10 Span:1067..1173
;Fish fed 4 ppb  AFB1 + 5 ppm PCB showed slight inhibition in response when
;compared with 4ppb  AFB1 alone.
;[1076..1077]:quantitative-value:"4"
;[1078..1081]:quantitative-units:"ppb"
;[1083..1087]:substance:"AFB1"
;[1090..1091]:quantitative-value:"5"
;[1092..1095]:quantitative-units:"ppm"
;[1096..1099]:substance:"PCB"
;[1156..1157]:quantitative-value:"4"
;[1157..1160]:quantitative-units:"ppb"
;[1162..1166]:substance:"AFB1"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1067..1071] Fish))
      (VP (VBN:[1072..1075] fed)
        (NP (-NONE-:[1075..1075] *))
        (NP
          (NP
            (NML (CD:[1076..1077] 4) (NN:[1078..1081] ppb))
            (NN:[1083..1087] AFB1))
          (SYM:[1088..1089] +)
          (NP
            (NML (CD:[1090..1091] 5) (NN:[1092..1095] ppm))
            (NN:[1096..1099] PCB)))))
    (VP (VBD:[1100..1106] showed)
      (NP
        (NP (JJ:[1107..1113] slight) (NN:[1114..1124] inhibition))
        (PP (IN:[1125..1127] in)
          (NP (NN:[1128..1136] response))))
      (SBAR-ADV
        (WHADVP-2 (WRB:[1137..1141] when))
        (S
          (NP-SBJ-1 (-NONE-:[1141..1141] *))
          (VP (VBN:[1142..1150] compared)
            (NP-1 (-NONE-:[1150..1150] *))
            (PP-CLR (IN:[1151..1155] with)
              (NP
                (NP
                  (NML (CD:[1156..1157] 4) (NN:[1157..1160] ppb))
                  (NN:[1162..1166] AFB1))
                (ADVP (RB:[1167..1172] alone))))
            (ADVP-TMP-2 (-NONE-:[1172..1172] *T*))))))
    (.:[1172..1173] .)))

;sentence 11 Span:1174..1282
;Also, livers from fish fed 50 ppm PCB were used to prepare S20 for  use in
;the Salmonella mutagenesis assay.
;[1201..1203]:quantitative-value:"50"
;[1204..1207]:quantitative-units:"ppm"
;[1208..1211]:substance:"PCB"
;[1233..1236]:substance:"S20"
(SENT
  (S
    (ADVP (RB:[1174..1178] Also))
    (,:[1178..1179] ,)
    (NP-SBJ-1
      (NP (NNS:[1180..1186] livers))
      (PP (IN:[1187..1191] from)
        (NP
          (NP (NNS:[1192..1196] fish))
          (VP (VBN:[1197..1200] fed)
            (NP (-NONE-:[1200..1200] *))
            (NP
              (NML (CD:[1201..1203] 50) (NN:[1204..1207] ppm))
              (NN:[1208..1211] PCB))))))
    (VP (VBD:[1212..1216] were)
      (VP (VBN:[1217..1221] used)
        (NP-1 (-NONE-:[1221..1221] *))
        (S-PRP
          (NP-SBJ (-NONE-:[1221..1221] *))
          (VP (TO:[1222..1224] to)
            (VP (VB:[1225..1232] prepare)
              (NP (NN:[1233..1236] S20))
              (PP (IN:[1237..1240] for)
                (NP
                  (NP (NN:[1242..1245] use))
                  (PP (IN:[1246..1248] in)
                    (NP (DT:[1249..1252] the)
                      (NML (NNP:[1253..1263] Salmonella)
                           (NN:[1264..1275] mutagenesis))
                      (NN:[1276..1281] assay))))))))))
    (.:[1281..1282] .)))

;sentence 12 Span:1283..1379
;These livers were less efficient in  converting AFB1 to a mutagen, when
;compared to control S20.
;[1331..1335]:substance:"AFB1"
;[1341..1348]:substance:"mutagen"
;[1375..1378]:substance:"S20"
(SENT
  (S
    (NP-SBJ (DT:[1283..1288] These) (NNS:[1289..1295] livers))
    (VP (VBD:[1296..1300] were)
      (ADJP-PRD (RBR:[1301..1305] less) (JJ:[1306..1315] efficient)
        (PP (IN:[1316..1318] in)
          (S-NOM
            (NP-SBJ (-NONE-:[1318..1318] *))
            (VP (VBG:[1320..1330] converting)
              (NP (NN:[1331..1335] AFB1))
              (PP (TO:[1336..1338] to)
                (NP (DT:[1339..1340] a) (NN:[1341..1348] mutagen)))))))
      (,:[1348..1349] ,)
      (SBAR-ADV
        (WHADVP-2 (WRB:[1350..1354] when))
        (S
          (NP-SBJ-1 (-NONE-:[1354..1354] *))
          (VP (VBN:[1355..1363] compared)
            (NP-1 (-NONE-:[1363..1363] *))
            (PP-CLR (TO:[1364..1366] to)
              (NP (NN:[1367..1374] control) (NN:[1375..1378] S20)))
            (ADVP-2 (-NONE-:[1378..1378] *T*))))))
    (.:[1378..1379] .)))

;sentence 13 Span:1380..1504
;The AFB1-mutagenesis  dose-response curve was again shifted parallel to the
;right of the curve  generated using control S20.
;[1384..1388]:substance:"AFB1"
;[1500..1503]:substance:"S20"
(SENT
  (S
    (NP-SBJ-1 (DT:[1380..1383] The)
      (NML (NN:[1384..1388] AFB1) (HYPH:[1388..1389] -)
           (NN:[1389..1400] mutagenesis))
      (NML
        (NML (NN:[1402..1406] dose))
        (PP (HYPH:[1406..1407] -)
          (NML (NN:[1407..1415] response))))
      (NN:[1416..1421] curve))
    (VP (VBD:[1422..1425] was)
      (ADVP (RB:[1426..1431] again))
      (VP (VBN:[1432..1439] shifted)
        (NP-1 (-NONE-:[1439..1439] *))
        (ADVP (JJ:[1440..1448] parallel)
          (PP (TO:[1449..1451] to)
            (NP
              (NP (DT:[1452..1455] the) (NN:[1456..1461] right))
              (PP (IN:[1462..1464] of)
                (NP
                  (NP (DT:[1465..1468] the) (NN:[1469..1474] curve))
                  (VP (VBN:[1476..1485] generated)
                    (NP (-NONE-:[1485..1485] *))
                    (S-MNR
                      (NP-SBJ (-NONE-:[1485..1485] *))
                      (VP (VBG:[1486..1491] using)
                        (NP (NN:[1492..1499] control) (NN:[1500..1503] S20))))))))))))
    (.:[1503..1504] .)))

;sentence 14 Span:1505..1612
;These results suggest that the inhibitory action is  at least partly at the
;level of carcinogen activation.
;[1590..1600]:substance:"carcinogen"
(SENT
  (S
    (NP-SBJ (DT:[1505..1510] These) (NNS:[1511..1518] results))
    (VP (VBP:[1519..1526] suggest)
      (SBAR (IN:[1527..1531] that)
        (S
          (NP-SBJ (DT:[1532..1535] the) (JJ:[1536..1546] inhibitory)
                  (NN:[1547..1553] action))
          (VP (VBZ:[1554..1556] is)
            (ADVP
              (ADVP (IN:[1558..1560] at) (JJS:[1561..1566] least))
              (RB:[1567..1573] partly))
            (PP-PRD (IN:[1574..1576] at)
              (NP
                (NP (DT:[1577..1580] the) (NN:[1581..1586] level))
                (PP (IN:[1587..1589] of)
                  (NP (NN:[1590..1600] carcinogen) (NN:[1601..1611] activation)))))))))
    (.:[1611..1612] .)))

;sentence 15 Span:1613..1863
;The finding of parallel,  as opposed to proportional, inhibition with varying
;carcinogen exposure for  certain classes of inhibitors may have important
;implications for inhibition of  environmental carcinogenesis at low levels of
;carcinogen exposure.
;[1691..1701]:substance:"carcinogen"
;[1735..1745]:substance:"inhibitors"
;[1843..1853]:substance:"carcinogen"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1613..1616] The) (NN:[1617..1624] finding))
      (PP (IN:[1625..1627] of)
        (NP
          (NP (JJ:[1628..1636] parallel))
          (,:[1636..1637] ,)
          (PP (IN:[1639..1641] as)
            (PP (VBN:[1642..1649] opposed)
              (PP (TO:[1650..1652] to)
                (NP (JJ:[1653..1665] proportional) (,:[1665..1666] ,)
                    (NN:[1667..1677] inhibition)))))))
      (PP (IN:[1678..1682] with)
        (NP (VBG:[1683..1690] varying) (NN:[1691..1701] carcinogen)
            (NN:[1702..1710] exposure)))
      (PP (IN:[1711..1714] for)
        (NP
          (NP (JJ:[1716..1723] certain) (NNS:[1724..1731] classes))
          (PP (IN:[1732..1734] of)
            (NP (NNS:[1735..1745] inhibitors))))))
    (VP (MD:[1746..1749] may)
      (VP (VB:[1750..1754] have)
        (NP
          (NP (JJ:[1755..1764] important) (NNS:[1765..1777] implications))
          (PP (IN:[1778..1781] for)
            (NP
              (NP (NN:[1782..1792] inhibition))
              (PP (IN:[1793..1795] of)
                (NP (JJ:[1797..1810] environmental)
                    (NN:[1811..1825] carcinogenesis)))
              (PP (IN:[1826..1828] at)
                (NP
                  (NP (JJ:[1829..1832] low) (NNS:[1833..1839] levels))
                  (PP (IN:[1840..1842] of)
                    (NP (NN:[1843..1853] carcinogen) (NN:[1854..1862] exposure))))))))))
    (.:[1862..1863] .)))

;section 16 Span:1867..1911
;PMID: 6436502 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1867..1871] PMID) (::[1871..1872] :) (CD:[1873..1880] 6436502)
        (NN:[1881..1882] -LSB-) (NNP:[1882..1888] PubMed) (::[1889..1890] -)
        (NN:[1891..1898] indexed) (IN:[1899..1902] for)
        (NNP:[1903..1911] MEDLINE-RSB-)))
